6.3 Neurobehavioral Sequelae and Agitation Management

ABPMR Physical Medicine and Rehabilitation Board Exam Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 ABPMR Part I Exam Overview & Format 1.2 Board Review Strategy & Content Blueprint Breakdown

2 Chapter 2: Musculoskeletal Medicine

2.1 Shoulder & Upper Extremity Diagnostics 2.2 Knee, Hip & Lower Extremity Conditions 2.3 Spine Pathology, Radiculopathy & Myelopathy 2.4 Inflammatory Arthritis, Tendinopathies & Concussion 2.5 Bone Health, Osteoporosis & Metabolic Bone Disease 2.6 Thoracic Outlet Syndrome & Peripheral Nerve Entrapment 2.7 Fracture Rehabilitation & Immobilization Complications 2.8 Overuse Tendinopathies & Regenerative Medicine 2.9 Gait Analysis & Abnormal Gait Patterns

3 Chapter 3: Spinal Cord Injury Rehabilitation

3.1 ASIA Examination & Impairment Scale 3.2 Spinal Cord Injury Syndromes 3.3 Autonomic Dysreflexia & Acute Complications 3.4 Neurogenic Bladder, Bowel & Secondary Complications

4 Chapter 4: Stroke & Neuromuscular Rehabilitation

4.1 Stroke Vascular Syndromes & Acute Assessment 4.2 Stroke Motor Recovery & Hemiplegic Complications 4.3 Spasticity Assessment & Multimodal Management 4.4 ALS, GBS, CIDP & Neuromuscular Disease Rehab 4.5 Multiple Sclerosis & Demyelinating Disease Rehabilitation 4.6 Parkinsonism, Movement Disorders & Functional Neurologic Disorder

5 Chapter 5: Electrodiagnostics (EMG/NCS)

5.1 Nerve Conduction Studies Principles & Physics 5.2 Needle Electromyography & MUAP Analysis 5.3 Mononeuropathies & Radiculopathy Patterns 5.4 Neuromuscular Junction Disorders & Myopathies

6 Chapter 6: Traumatic Brain Injury

6.1 TBI Severity Classification, Glasgow Coma Scale, and Pathophysiology 6.2 Rancho Los Amigos Levels of Cognitive Functioning and Disability Rating Scale 6.3 Neurobehavioral Sequelae and Agitation Management 6.4 Concussion Evaluation, Vestibular-Ocular Dysfunction, and Return-to-Play/Work Protocols

7 Chapter 7: Chronic Pain & Interventional Spine

7.1 Fluoroscopic Spine Interventions 7.2 Opioid Stewardship & Controlled Substance Compliance 7.3 Complex Regional Pain Syndrome, Fibromyalgia & Myofascial Pain 7.4 Spinal Cord Stimulation & Intrathecal Therapy

8 Chapter 8: Amputee Rehabilitation & Prosthetics

8.1 Amputation Surgical Levels & Medicare K-Levels 8.2 Socket Designs & Suspension Systems 8.3 Prosthetic Feet & Microprocessor Knee Mechanisms 8.4 Post-Amputation Care, Residual Limb & Phantom Pain

9 Chapter 9: Pediatric Rehabilitation

9.1 Cerebral Palsy Classification & GMFCS 9.2 Spina Bifida & Myelomeningocele Management 9.3 Muscular Dystrophies & Neuromuscular Disease in Children 9.4 Pediatric Brachial Plexopathy & Congenital Disorders

10 Chapter 10: Prosthetics, Orthotics & Assistive Technology

10.1 Lower Limb Orthoses — AFOs & KAFOs 10.2 Spinal & Upper Extremity Orthoses 10.3 Upper Limb Prosthetics — Body-Powered vs Myoelectric 10.4 Wheelchairs, Seating Systems & Pressure Mapping

11 Chapter 11: Medical Rehabilitation & Outcomes

11.1 Dysphagia Assessment & Management 11.2 Neurogenic Bladder & Bowel Management 11.3 Pressure Injuries & Wound Management 11.4 Outcome Measures & Medical Complications 11.5 Cancer Rehabilitation & Oncologic Rehabilitation 11.6 Burns, Endocrine/Metabolic & Medical Complications Rehabilitation

12 Chapter 12: Cardiopulmonary Rehabilitation

12.1 Cardiac Rehabilitation Phases & Metabolic Equivalents 12.2 Pulmonary Rehabilitation & COPD Management

13 Chapter 13: Foundational Rehabilitation Concepts

13.1 Kinesiology, Biomechanics & Functional Anatomy 13.2 Rehabilitation Pharmacology & Medication Management 13.3 Research Methodology, Biostatistics & Evidence-Based Practice 13.4 Nutrition, Metabolism & Energy Expenditure in Rehabilitation 13.5 Diagnostic Procedures: Imaging, MSK Ultrasound, Urodynamics & Neuropsych Assessment

6.3 Neurobehavioral Sequelae and Agitation Management

Key Takeaways Explain This Topic AI

Post-traumatic agitation occurs predominantly during Rancho Level IV recovery; first-line management requires systematic evaluation to rule out underlying medical and physiological causes of pain or discomfort.

Non-pharmacologic and environmental interventions (low stimulation, structured routines, private rooms, Posey/Craig padded enclosure beds) must always be maximized before or alongside pharmacotherapy.

Amantadine (100 mg BID) is a dopaminergic agonist and NMDA receptor antagonist proven in randomized controlled trials to accelerate functional neurorecovery, arousal, and cognitive speed in acute/subacute TBI.

Propranolol (high-dose beta-blocker) is first-line pharmacotherapy for hyperadrenergic central agitation and autonomic dysregulation after TBI.

ABSOLUTE CONTRAINDICATIONS: Benzodiazepines and typical antipsychotics (e.g., haloperidol) MUST BE AVOIDED in acute/subacute TBI due to inhibition of neural plasticity, suppression of cognitive recovery, and motor deficit worsening.

Last updated: July 2026

6.3 Neurobehavioral Sequelae and Agitation Management

Neurobehavioral disturbances are among the most distressing and challenging sequelae following traumatic brain injury (TBI). Post-traumatic agitation, aggression, impulsivity, apathy, and executive disinhibition create major hurdles for acute rehabilitation, increase caregiver burden, and risk bodily harm to patients and medical staff. Physiatrists must apply a structured approach to post-TBI neurobehavioral management—prioritizing medical workups, environmental modifications, and evidence-based neuropharmacology while strictly avoiding medications that impair neural plasticity.

Post-Traumatic Agitation and Rancho Level IV

Post-traumatic agitation is defined as a sub-syndrome of confusion, akathisia, motor restlessness, emotional lability, and aggressive behavior occurring during the period of post-traumatic amnesia (most commonly at Rancho Level IV ).

Systematic Medical Rule-Out ("Search for Pain First")

Before attributing agitation solely to brain injury, physiatrists MUST systematically search for and treat underlying physiological and environmental causes of pain, distress, or delirium: +-------------------------------------------------------------------------+

| SYSTEMATIC WORKUP FOR POST-TBI AGITATION |
+------------------------+------------------------------------------------+
| Clinical Category | Specific Underlying Reversible Triggers |
+------------------------+------------------------------------------------+
| Genitourinary | Urinary retention, bladder distension, UTI, |
| | blocked Foley catheter |
+------------------------+------------------------------------------------+
| Gastrointestinal | Constipation, severe fecal impaction, bowel |
| | distension, GERD |
+------------------------+------------------------------------------------+
| Musculoskeletal / Trauma| Occult bone fractures, heterotopic ossification|
| | (HO), compartment syndrome, spasticity pain |
+------------------------+------------------------------------------------+
| Neurological | Post-traumatic hydrocephalus, increased ICP, |
| | occult seizures, subdural hematoma expansion |
+------------------------+------------------------------------------------+
| Metabolic / Systemic | Hypoxia, hyponatremia, hypoglycemia, central |
| | fever, systemic infection / sepsis |
+------------------------+------------------------------------------------+
| Iatrogenic / Device | Tight physical restraints, endotracheal/trach |
| | irritation, IV line infiltration, withdrawal |
+------------------------+------------------------------------------------+
Non-Pharmacologic and Environmental Interventions

Non-pharmacologic strategies form the foundational baseline of agitation management and should be implemented immediately:

Environmental De-stimulation :

Place the patient in a private room away from noisy nursing stations.

Dim overhead lighting, turn off alarms/televisions, and limit visitors to one or two calm family members.

Use simple, concise, low-tone verbal communication.

Safety Enclosure Beds (Posey Bed / Craig Bed) :

Padded mesh enclosure beds allow the patient to move, turn, and roll safely without risk of falling out of bed.

Crucial Benefit : Replaces traditional physical wrist or vest restraints, which severely exacerbate agitation, frustration, and combativeness.

Structured Rehabilitation Routine :

Maintain consistent nursing staff, predictable therapy schedules, and prominent orientation boards (calendar, clock, names of care team).

Single-tasking during therapy; allow frequent rest breaks to prevent cognitive fatigue.

Neuropharmacology for Agitation and Neurorecovery

When non-pharmacologic measures are insufficient, neuropharmacotherapy is initiated. Medications should be selected based on their specific mechanism, target symptom profile, and positive effect on neurorecovery. +---------------------------------------------------------------------------------------------------+

| EVIDENCE-BASED PHARMACOTHERAPY FOR POST-TBI AGITATION |
+-------------------+---------------------------+-----------------------+---------------------------+
| Medication | Primary Mechanism | Target Symptoms | Key Clinical Pearls |
+-------------------+---------------------------+-----------------------+---------------------------+
| **Amantadine** | Dopamine agonist & | Arousal, cognitive | **Level A Evidence** for |
| | NMDA receptor antagonist | speed, agitation | accelerating recovery; |
| | | | Dose: 100 mg BID. |
+-------------------+---------------------------+-----------------------+---------------------------+
| **Propranolol** | Lipophilic non-selective | Central agitation, | Titrate to high doses |
| | beta-blocker | hyperadrenergic drive,| (120-480 mg/day); monitor |
| | | violent outbursts | HR and BP. |
+-------------------+---------------------------+-----------------------+---------------------------+
| **Buspirone** | 5-HT1A receptor partial | Subacute/chronic | Non-sedating; no memory |
| | agonist | agitation, anxiety, | impairment; requires 1-2 |
| | | irritability | weeks for onset. |
+-------------------+---------------------------+-----------------------+---------------------------+
| **Divalproex** | GABA enhancer & sodium | Persistent aggression,| First-line anticonvulsant |
| **(Valproate)** | channel blocker | mood lability | mood stabilizer; minimal |
| | | | cognitive suppression. |
+-------------------+---------------------------+-----------------------+---------------------------+
| **Trazodone** | 5-HT2A antagonist & H1 | Sleep-wake cycle | Choice agent for nocturnal|
| | receptor antagonist | disruption, night | agitation; low risk of |
| | | agitation | anticholinergic toxicity. |
+-------------------+---------------------------+-----------------------+---------------------------+
Detailed Clinical Pharmacology
1. Amantadine (Dopamine Agonist / NMDA Antagonist)

Indications : Impaired arousal, slow cognitive processing speed, disorders of consciousness, and post-TBI agitation.

Landmark Evidence : A seminal multicenter randomized controlled trial (Giacino et al., NEJM 2012) demonstrated that amantadine 100 mg twice daily administered during acute inpatient rehabilitation significantly accelerated the rate of functional cognitive and motor recovery in patients with severe TBI.

Dosing : Start 50-100 mg daily in the morning, titrating to 100 mg BID (morning and noon to prevent insomnia). Excreted renally (adjust for renal impairment).

2. Propranolol (Central Beta-Blocker)

Indications : Central sympathetic hyperactivity ("storming"), akathisia, impulsivity, and violent aggressive outbursts.

Mechanism : High lipophilicity enables rapid blood-brain barrier penetration, blocking central noradrenergic overdrive originating from locus coeruleus hyperresponsiveness.

Dosing : Initial 10-20 mg TID, titrating aggressively up to 120–480 mg/day as blood pressure and heart rate permit.

3. Divalproex Sodium / Valproic Acid

Indications : Chronic agitation, affective lability, impulse control disorders, and post-traumatic epilepsy prophylaxis.

Advantage : Superior cognitive profile compared to carbamazepine or phenytoin, with minimal impact on learning and memory.

ABSOLUTE CONTRAINDICATIONS: Medications to AVOID

A critical concept tested on board examinations is identifying medications that impair neural recovery and must be strictly avoided during post-TBI rehabilitation. +---------------------------------------------------------------------------------------------------+

| MEDICATIONS STRICTLY CONTRAINDICATED IN ACUTE TBI REHAB |
+-------------------+-----------------------------------+-------------------------------------------+
| Drug Class | Specific Exemplar Agents | Mechanism of Harm & Adverse Impact |
+-------------------+-----------------------------------+-------------------------------------------+
| **Benzodiazepines**| Lorazepam, Diazepam, Alprazolam, | - Impairs activity-dependent synaptogenesis|
| | Midazolam | - Suppresses motor and cognitive recovery |
| | | - Causes **paradoxical disinhibition** |
| | | - Severe memory impairment & fall risk |
+-------------------+-----------------------------------+-------------------------------------------+
| **Typical** | Haloperidol, Fluphenazine, | - Blocks central D2 dopamine receptors |
| **Antipsychotics**| Chlorpromazine | - **Halts motor functional recovery** |
| | | - Induces EPS & lowers seizure threshold |
| | | - Exacerbates cognitive deficits |
+-------------------+-----------------------------------+-------------------------------------------+
| **Anticholinergics**| Diphenhydramine, Hydroxyzine, | - Blocks central muscarinic M1 receptors |
| | Oxybutynin, Scopolamine | - Causes acute delirium & memory failure |
| | | - Inhibits cholinergic neurorecovery |
+-------------------+-----------------------------------+-------------------------------------------+

Board Alert: Preclinical and clinical studies (e.g., Feeney et al.) demonstrate that administering haloperidol or benzodiazepines following brain injury permanently delays or prevents motor recovery. If an antipsychotic is absolutely mandatory for severe, refractory psychosis threatening immediate life safety, use short-term atypical antipsychotics with low D2 affinity (e.g., Quetiapine or Olanzapine) at the lowest effective dose.